789 - Viral and Immunologic biomarkers of COVID-19 improve risk stratification and identify patients most likely to benefit from therapy with remdesivir

Thursday, October 20, 2022

4:15 PM – 4:30 PM US ET

Location: 147 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Presenting Author(s)

Kanal Singh, MD, MPH

Clinical Fellow
The National Institute of Allergy and Infectious Diseases, National Institutes of Health
Bethesda, MD, United States

Disclosure: Disclosure(s): No financial relationships to disclose

Co-Author(s)

KR

Kevin Rubenstein, MS

Frederick National Laboratory
Rockville, Maryland, United States

Disclosure: Disclosure(s): Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()
VC

Viviane Callier, PhD

Frederick National Laboratory
Rockville, Maryland, United States

Disclosure: Disclosure(s): Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()
KS

Katy Shaw-Saliba, PhD

The National Institute of Allergy and Infectious Diseases, National Institutes of Health
Bethesda, Maryland, United States

Disclosure: Disclosure(s): No financial relationships to disclose
AR

Adam Rupert, n/a

Frederick National Laboratory
Rockville, Maryland, United States

Disclosure: Disclosure(s): Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()
RD

Robin L. Dewar, PhD

Senior Principal Scientist
Frederick National Laboratory
Rockville, Maryland, United States

Disclosure: Disclosure(s): Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()
SL

Sylvain Laverdure, n/a

Frederick National Laboratory
Rockville, Maryland, United States

Disclosure: Disclosure(s): Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()
HH

Helene Highbarger, n/a

Research Scientist
Frederick National Laboratory
Rockville, Maryland, United States

Disclosure: Disclosure(s): Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()
PL

Perrine Lallemand, n/a

Research Scientist
Frederick National Laboratory
Rockville, Maryland, United States

Disclosure: Disclosure(s): Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()
MH

Meei-Li Huang, PhD

Research Scientist
University of Washington
Seattle, Washington, United States

Disclosure: Disclosure(s): No financial relationships to disclose
KJ

Keith R. Jerome, MD PhD

Professor
Fred Hutchinson Cancer Center
Seattle, Washington, United States

Disclosure: Disclosure(s): No financial relationships to disclose
RS

Reigran Sampoleo, n/a

University of Washington
Seattle, Washington, United States

Disclosure: Disclosure(s): No financial relationships to disclose
MM

Margaret Mills, n/a

University of Washington
Seattle, Washington, United States

Disclosure: Disclosure(s): No financial relationships to disclose
DP

Danielle P. Porter, PhD

Sr. Director
Gilead Sciences Inc
Foster City, California, United States

Disclosure: Disclosure(s): Gilead: Stocks/Bonds ()
KJ

Kavita Juneja, n/a

Clinical Research
Gilead Sciences Inc
Foster City, California, United States

Disclosure: Disclosure(s): Gilead Sciences: Employee ()
AG

Alexander L. Greninger, MD, PhD

Assistant Professor
University of Washington
Seattle, Washington, United States

Disclosure: Disclosure(s): Abbott: Contract testing (); Cepheid: Contract testing (); Gilead: Grant/Research Support (); Hologic: Contract testing (); Janssen: Contract testing (); Merck: Grant/Research Support (); Novavax: Contract testing (); Pfizer: Contract testing ()
HL

H. Clifford Lane, MD

Clinical Director
The National Institute of Allergy and Infectious Diseases, National Institutes of Health
Bethesda, Maryland, United States

Disclosure: Disclosure(s): No financial relationships to disclose
JB

John H. Beigel, MD

The National Institute of Allergy and Infectious Diseases, National Institutes of Health
Rockville, Maryland, United States

Disclosure: Disclosure(s): No financial relationships to disclose
LD

Lori E. Dodd, PhD

Section Chief, Biostatistician
The National Institute of Allergy and Infectious Diseases, National Institutes of Health
Rockville, Maryland, United States

Disclosure: Disclosure(s): No financial relationships to disclose

Disclosure(s):

Kanal Singh, MD, MPH: No financial relationships to disclose

Kevin Rubenstein, MS: Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()

Viviane Callier, PhD: Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()

Katy Shaw-Saliba, PhD: No financial relationships to disclose

Adam Rupert, n/a: Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()

Robin L. Dewar, PhD: Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()

Sylvain Laverdure, n/a: Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()

Helene Highbarger, n/a: Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()

Perrine Lallemand, n/a: Frederick National Laboratory: Funded by the NCI Contract No. 75N91019D00024 ()

Meei-Li Huang, PhD: No financial relationships to disclose

Keith R. Jerome, MD PhD: No financial relationships to disclose

Reigran Sampoleo, n/a: No financial relationships to disclose

Margaret Mills, n/a: No financial relationships to disclose

Danielle P. Porter, PhD: Gilead: Stocks/Bonds ()

Kavita Juneja, n/a: Gilead Sciences: Employee ()

Alexander L. Greninger, MD, PhD: Abbott: Contract testing (); Cepheid: Contract testing (); Gilead: Grant/Research Support (); Hologic: Contract testing (); Janssen: Contract testing (); Merck: Grant/Research Support (); Novavax: Contract testing (); Pfizer: Contract testing ()

H. Clifford Lane, MD: No financial relationships to disclose

John H. Beigel, MD: No financial relationships to disclose

Lori E. Dodd, PhD: No financial relationships to disclose